IntelliPharmaCeutics International (IntelliPharmaCeutics International) Effective Interest Rate on Debt % : 12.01% (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. IntelliPharmaCeutics International's annualized positive value of Interest Expense for the quarter that ended in Aug. 2023 was $0.27 Mil. IntelliPharmaCeutics International's average total debt for the quarter that ended in Aug. 2023 was $2.23 Mil. Therefore, IntelliPharmaCeutics International's annualized Effective Interest Rate on Debt % for the quarter that ended in Aug. 2023 was 12.01%.

IntelliPharmaCeutics International Effective Interest Rate on Debt % Historical Data

The historical data trend for IntelliPharmaCeutics International's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Effective Interest Rate on Debt % Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Effective Interest Rate on Debt %

Get a 7-Day Free Trial

16.56

13.42

48.28

27.25

13.76

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Effective Interest Rate on Debt %	Get a 7-Day Free Trial															10.45	12.01	8.82	9.16	12.01

Competitive Comparison of IntelliPharmaCeutics International's Effective Interest Rate on Debt %

For the Biotechnology subindustry, IntelliPharmaCeutics International's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Effective Interest Rate on Debt % falls into.

IntelliPharmaCeutics International Effective Interest Rate on Debt % Calculation

IntelliPharmaCeutics International's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Nov. 2022 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (A: Nov. 2021 )	+	Total Debt (A: Nov. 2022 ))	/ count )
=	-1 * -0.292	/	( (1.917	+	2.326)	/ 2 )
=	-1 * -0.292	/	2.1215
=	13.76 %

where

	Total Debt (A: Nov. 2021 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	1.917
=	1.917

	Total Debt (A: Nov. 2022 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.326
=	2.326

IntelliPharmaCeutics International's annualized Effective Interest Rate on Debt % for the quarter that ended in Aug. 2023 is calculated as

	Effective Interest Rate on Debt %
=	-1 * Interest Expense	/	( (Total Debt (Q: May. 2023 )	+	Total Debt (Q: Aug. 2023 ))	/ count )
=	-1 * -0.268	/	( (2.244	+	2.218)	/ 2 )
=	-1 * -0.268	/	2.231
=	12.01 %

where

	Total Debt (Q: May. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.244
=	2.244

	Total Debt (Q: Aug. 2023 )
=	Long-Term Debt & Capital Lease Obligation	+	Short-Term Debt & Capital Lease Obligation
=	0	+	2.218
=	2.218

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Aug. 2023) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.

IntelliPharmaCeutics International (OTCPK:IPCIF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.

IntelliPharmaCeutics International Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Effective Interest Rate on Debt %

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.